Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

Final thoughts on the Pralatrexate/Romidepsin abstract and PR.
First, the abstract presented at the 14-ICML Meeting is a good advertisement for recruitment of the P2 part of the study and I’m sure will help speed up recruitment. Lymphoma docs have been reinforced on the merits of this trial and should send patients the trials way. Secondly, I wouldn’t be that surprised if they present some interim data at ASH 2017 in December. The previous abstract was presented at ASH 2016 and for an abstract to be included at that meeting, the abstract would have to be submitted for review at the very beginning of August 2016. If you figure it would take a couple of months to write the abstract, IMO, that could very well mean the P2 phase of the trial started in early to mid-summer 2016; that’s a year of recruitment of the P2 under its belt. Thirdly, the P1 was the dose range finding part of the study and now they’ll dose all the pts at the higher Folotyn dose which I would expect will improve outcome.